Hostname: page-component-77c89778f8-m42fx Total loading time: 0 Render date: 2024-07-19T23:23:00.351Z Has data issue: false hasContentIssue false

Metabolic syndrome in schizophrenia -impact of antipsychotic medication

Published online by Cambridge University Press:  16 April 2020

T.M.-S. Maria-Silvia*
Affiliation:
UMF Carol Davila Bucharest, Bucharest, Romania

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Metabolic syndrome generally includes some or all of the following: elevated blood pressure, abdominal obesity, diabetes or “prediabetes” (impaired glucose tolerance, impaired fasting glucose or insulin resistance), dyslipidemia (high levels of triglycerides and/or HDL), and inflammatory markers

P.S. a 34 year old, diagnosed with Paranoid schizophrenia. The patient comes from a disorganised family. The disease started at 18 years with psychotic symptoms - delirious, psychotic behavior, aggression, neglect of personal hygiene. He received almost continuous antipsychotic medication. In recent years received the second generation antipsychotic medication. Under this medication increased weight reaching 160 kg in weight. The most significant weight gain occurred in recent years under neuroleptic medication with clozapinum. Hypertension (max 200/120) appeared as a complication of increased weight, requiring antihypertensive medication. Has not other endocrine problems. Laboratory values increased cholesterol, triglyceride, and lipid. Glycemia remained normal. In the last six months patient received amisulpiridum 800 mg/day. In same conditions of life the patient has lost 40 kg in weight reaching 140 kg. Family history- mother obesity and HTA;Weight and (BMI) initially 160kg/180 cm then 120 kg/180 cm;Waist circumference 140 cm;Blood pressure initially 200/120 mm Hg then160 /110 mmhg;Fasting lipids increased,glucose normal Conclusion: Assessment of risk factors is necessary before prescription of antipsychotics. Especially weight, BMI, family history for obesity, and ethnicity should be evaluated. People taking antipsychotics that increase the risk of MetS should be educated on this subject. They should be advised about their diet and lifestyle, about how to recognize symptoms of MetS and its consequences.

Type
P03-86
Copyright
Copyright © European Psychiatric Association 2011
Submit a response

Comments

No Comments have been published for this article.